Polygenic Determinants of Alzheimer's Disease: Modulation of the Risk by α‐1‐Antichymotrypsina
- 17 December 1996
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 802 (1) , 27-34
- https://doi.org/10.1111/j.1749-6632.1996.tb32595.x
Abstract
The identification of apolipoprotein E (APOE) as a genetic risk factor modifying the chances of developing Alzheimer's disease (AD) has opened the possibility that other susceptibility genes exist that either independently modify the risk of developing AD or alter the risk imparted by APOE. We have identified alpha-1-antichymotrypsin (ACT) as a potential risk gene, by virtue of the interactive effect of either of its two alleles (A and T) on the risk of AD associated with the APOE epsilon 4 allele. In a large population of AD (n = 308) and control (n = 579) cohorts, we found the expected elevation in the APOE epsilon 4 allele frequency in the AD cases compared to controls, with threefold and sevenfold increases in the risk of AD for APOE epsilon 4/X and APOE epsilon 4/epsilon 4, respectively. Of the three ACT genotypes, the ACT A/T genotype did not affect the risk of AD beyond that which is conferred by the APOE epsilon 4 allele. However, the ACT A/A genotype greatly increased the risk associated with APOE epsilon 4 homozygosity. On the other hand, the ACT T/T genotype suppressed the gene dosage effect of the APOE epsilon 4 allele; the risk of AD in APOE epsilon 4/epsilon 4, ACT T/T cases was the same as that of APOE epsilon 4/X. A variety of potential mechanisms for interactions of ACT and APOE are discussed.Keywords
This publication has 20 references indexed in Scilit:
- A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphismNature Genetics, 1995
- Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's diseaseAnnals of Neurology, 1995
- Elevated Alpha1-Antichymotrypsin Serum Levels in a Subset of Nondemented First-Degree Relatives of Alzheimer's Disease PatientsDementia and Geriatric Cognitive Disorders, 1995
- The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, ColoradoAtherosclerosis, 1995
- Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filamentsNature, 1994
- Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactionsNeuron, 1993
- α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementiaAnnals of Neurology, 1990
- Unity in Function in the Absence of Consensus in Sequence: Role of Leader Peptides in ExportScience, 1989
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984